Company intelligence / Profile preview

Nervotec

Ownership: Private
Development stage: Commercial

Overview

Nervotec has developed a commercialized remote photoplethysmography (rPPG) platform that enables non-contact measurement of vital signs using standard cameras. The system is used in healthcare engagement apps, insurance risk assessment tools, and to facilitate remote data collection in clinical trials. No drug or therapeutic clinical results are reported as the company is not a drug developer.

Therapeutic areas: OtherPsychiatryCardiovascular
Modalities: DeviceNon-pharmacological therapyDigital biomarker platform
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Nervotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nervotec.

Explore the full profile